GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Endologix Inc (OTCPK:ELGXQ) » Definitions » Gross Margin %

Endologix (Endologix) Gross Margin % : 56.97% (As of Jun. 2020)


View and export this data going back to 1996. Start your Free Trial

What is Endologix Gross Margin %?

Gross Margin % is calculated as gross profit divided by its revenue. Endologix's Gross Profit for the three months ended in Jun. 2020 was $14.2 Mil. Endologix's Revenue for the three months ended in Jun. 2020 was $24.8 Mil. Therefore, Endologix's Gross Margin % for the quarter that ended in Jun. 2020 was 56.97%.


The historical rank and industry rank for Endologix's Gross Margin % or its related term are showing as below:


ELGXQ's Gross Margin % is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: 53.37
* Ranked among companies with meaningful Gross Margin % only.

Endologix had a gross margin of 56.97% for the quarter that ended in Jun. 2020 => Durable competitive advantage

The 5-Year average Growth Rate of Gross Margin for Endologix was 0.00% per year.


Endologix Gross Margin % Historical Data

The historical data trend for Endologix's Gross Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Endologix Gross Margin % Chart

Endologix Annual Data
Trend Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19
Gross Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 66.27 64.17 66.97 58.75 63.53

Endologix Quarterly Data
Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20
Gross Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 63.43 64.50 61.06 53.08 56.97

Competitive Comparison of Endologix's Gross Margin %

For the Medical Instruments & Supplies subindustry, Endologix's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Endologix's Gross Margin % Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Endologix's Gross Margin % distribution charts can be found below:

* The bar in red indicates where Endologix's Gross Margin % falls into.



Endologix Gross Margin % Calculation

Gross Margin is the percentage of Gross Profit out of sales or Revenue.

Endologix's Gross Margin for the fiscal year that ended in Dec. 2019 is calculated as

Gross Margin % (A: Dec. 2019 )=Gross Profit (A: Dec. 2019 ) / Revenue (A: Dec. 2019 )
=91.1 / 143.37
=(Revenue - Cost of Goods Sold) / Revenue
=(143.37 - 52.284) / 143.37
=63.53 %

Endologix's Gross Margin for the quarter that ended in Jun. 2020 is calculated as


Gross Margin % (Q: Jun. 2020 )=Gross Profit (Q: Jun. 2020 ) / Revenue (Q: Jun. 2020 )
=14.2 / 24.841
=(Revenue - Cost of Goods Sold) / Revenue
=(24.841 - 10.688) / 24.841
=56.97 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


Endologix  (OTCPK:ELGXQ) Gross Margin % Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

Endologix had a gross margin of 56.97% for the quarter that ended in Jun. 2020 => Durable competitive advantage


Be Aware

If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.


Endologix Gross Margin % Related Terms

Thank you for viewing the detailed overview of Endologix's Gross Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Endologix (Endologix) Business Description

Traded in Other Exchanges
N/A
Address
2 Musick, Irvine, CA, USA, 92618
Endologix Inc develops, manufacture, market, and sell innovative medical devices for the treatment of aortic disorders in the United States and internationally. The company only reporting segment that is focused on the development, manufacture, marketing, and sale of EVAR and EVAS products for the treatment of aortic disorders. It product Includes a variety of endovascular stent grafts for the treatment of abdominal aortic aneurysms such as AFX Endovascular AAA System, VELA Proximal Endograft, and Ovation Abdominal Stent Graft System. The firm generates the majority of its revenue in the United States.
Executives
Dan Lemaitre director 2 MUSICK, IRVINE CA 92618
Gregory D Waller director 1717 W COLLINS AVENUE, ORANGE CA 92867
John Onopchenko director, officer: CEO and Director C/O VOLCANO CORPORATION 11455 EL CAMINO REAL, SUITE 460 SAN DIEGO CA 92130
Thomas Wilder director 2 MUSICK, IRVINE CA 92618
Matthew Thompson officer: Chief Medical Officer 2 MUSICK, IRVINE CA 92618
Timothy Nicholas Brady officer: Controller and Corp Secretary 2 MUSICK IRVINE CA 92618
Cynthia Buch Pinto officer: Interim CFO 2 MUSICK IRVINE CA 92618
Jeff Fecho officer: Chief Quality Officer ONE ST. JUDE MEDICAL DRIVE ST. PAUL MN 55117
Richard W Mott director 1221 CROSSMAN AVENUE, SUNNYVALE CA 94089
Vaseem Mahboob officer: Chief Financial Officer 2 MUSICK IRVINE CA 92618
Jane E Kiernan director 525 W ROSCOE, CHICAGO IL 60657
John Zehren officer: Chief Commercial Officer 2 MUSICK IRVINE CA 92618
Jeremy B. Hayden officer: General Counsel 2 MUSICK, 2 MUSICK, IRVINE CA 92618
Leslie V Norwalk director C/O 3661 VALLEY CENTRE DRIVE SUITE 200, SAN DIEGO CA 92130
Zenty Iii Thomas F director 2 MUSICK IRVINE CA 92618